$40.70
-1.37-3.26%
Last update: Oct 23, 4:00 PM
Supernus Pharmaceuticals Inc (SUPN) Stock Price, Quote, News & History
SUPNNASDAQ
Supernus to acquire Sage Therapeutics for $795 million, gaining Zurzuvae and aiming for $200 million in annual cost synergies by expanding its CNS portfolio.
You can purchase shares of Supernus Pharmaceuticals (NASDAQ:SUPN) through any online brokerage.
Other companies in Supernus Pharmaceuticals’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).
Supernus Pharmaceuticals has a consensus price target of $62.40.
The stock price for Supernus Pharmaceuticals (NASDAQ: SUPN) is $40.7 last updated October 23, 2026 at 4:00 PM EDT.
There are no upcoming dividends for Supernus Pharmaceuticals.
Supernus Pharmaceuticals does not have any upcoming earnings scheduled.
There is no upcoming split for Supernus Pharmaceuticals.
Supernus Pharmaceuticals is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse...
